Navigation Links
Genedata Announces Collaboration With AstraZeneca on the Analysis of Compound Combination Experiments
Date:12/3/2013

Basel, Switzerland (PRWEB) December 03, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced its successful collaboration with AstraZeneca on data analysis for compound combination experiments. Drug combination studies, which are increasingly used in pre-clinical research, produce large volumes of data with upwards to 200 combinations per experiment. Genedata Screener, which has been proven to work as an easy and efficient platform for analyzing compound screening, has been advanced through the AstraZeneca collaboration as Genedata Screener now automates and standardizes the analysis of compound combination experiments.

“With Genedata, we are able to extract the highest value possible from our compound combination experiments,” noted Dr. Eric Tang, associate principle scientist at AstraZeneca. “Typically, compound combination experiments compare 50 or more compounds across a number of cell lines in a single study, resulting in the analysis of hundreds of 384/1536 well plates. Genedata Screener can handle these large data sets and enable us to generate and compare results for the same compound combinations in different cell lines, and review alternative analysis for the same data sets. Moreover, Screener helps standardize data analysis giving us more quality time to conduct detailed analysis,” continued Dr. Tang.

From Raw Data to Synergy Scores in Minutes
Combination therapies – the simultaneous use of a variety of drugs to treat a range of diseases from infections to cancer – have gained importance as a cure. And, compound combination experiments are a resurging trend in lead optimization and target validation. Data sets from these experiments tend to be large, as the number of measurements scales exponentially with the number of compounds to be compared. Genedata Screener effectively addresses the data analysis challenges of these large data sets by enabling researchers to:

  • Go from raw data to results in less than 30 minutes, also for large studies
  • Eliminate time-consuming manual data processing
  • Interactively inspect raw data and check the quality of normalized values
  • Review in-depth intermediate and final results using combination-specific displays such as concentration matrices and isobolograms
  • Automatically fit both mono-therapeutic and combination dose-response curves for quick and robust results
  • Display, quantify and compare measured and expected combination effects for different interaction models such as Loewe, Highest Single Agent, or Bliss
  • Access all processing steps throughout the workflow
“We see a huge demand for software that efficiently analyzes compound combination experiments in novel drug discovery,” said Dr. Othmar Pfannes, CEO of Genedata. “Our successful collaboration with AstraZeneca, a leader in combination therapies, helps us to further advance Genedata Screener as the platform of choice for the efficient analysis of compound combination experiments.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11324964.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biogas Consortium Using Genedata Selector for Metagenomics-based Process Optimization
2. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
3. Evonik and Genedata Broaden Their Collaboration with the Genedata Selector Biotechnology Data Management Platform
4. Genedata Screener Global User Group Meetings Will Examine Advancements in Plate-based Screening
5. Genedata Screener Extends Support for High-Throughput Thermofluor Assays
6. Genedata at ESACT Announces Expansion Into Biopharma Process Development
7. New Genedata Expressionist for Mass Spectrometry Showcases at 2013 ASMS
8. AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization
9. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
10. Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
11. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 02, 2016 ... ... a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved ... interested in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
(Date:11/30/2016)... today announced the appointment of Joshua F. Coleman , ... Dr. Coleman will oversee clinical content development and curation of ... software suite empowers molecular pathologists with a seamless workflow for ... from quality control through reporting. ... , , ...
(Date:11/30/2016)... RATON, Fla. , Nov. 30, 2016 ... biotherapeutic products, is pleased to announce the addition of ... Avenue Kearney, Nebraska . The 15,200 ... business on November 29th, 2016 and brings the total ... Ileana Carlisle , BPC,s Chief Executive ...
Breaking Biology Technology:
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
Breaking Biology News(10 mins):